Aytu BioPharma (NASDAQ:AYTU) Stock Rating Upgraded by Zacks Research

Aytu BioPharma (NASDAQ:AYTU) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Wall Street Zen raised Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $2.30 on Monday. Aytu BioPharma has a one year low of $1.26 and a one year high of $3.07. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. The business has a fifty day moving average of $2.59 and a two-hundred day moving average of $2.44. The company has a market cap of $24.68 million, a P/E ratio of -0.60 and a beta of 0.28.

Hedge Funds Weigh In On Aytu BioPharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Daytona Street Capital LLC acquired a new position in Aytu BioPharma during the 4th quarter worth approximately $26,000. Rothschild Wealth LLC purchased a new position in shares of Aytu BioPharma during the 4th quarter valued at approximately $52,000. Dimensional Fund Advisors LP acquired a new stake in shares of Aytu BioPharma during the 3rd quarter valued at approximately $58,000. Bellevue Asset Management LLC acquired a new stake in shares of Aytu BioPharma during the 4th quarter valued at approximately $65,000. Finally, XTX Topco Ltd acquired a new stake in shares of Aytu BioPharma during the 4th quarter valued at approximately $67,000. 33.49% of the stock is owned by institutional investors and hedge funds.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.